Document Type : Research articles

Authors

Research Center for Anesthesiology, Critical Care, and Pain Management, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Abstract

Background: The prevalence of ventricular fibrillation after removal of the aortic cross - clamp in patients undergoing coronary artery bypass surgery is about 74% - 96%. Defibrillation shock and different types of agents are used to treat ventricular fibrillation (VF). Objectives: This study was aimed to compare the effects of combining Lidocaine + Magnesium Sulfate with Amiodarone + Magne- sium Sulfate in the prevention of reperfusion - induced ventricular fibrillation.
Methods: This randomized, double- blinded clinical study included 74 ASA class II and III patients undergoing coronary artery by- pass grafting (CABG) in a university - affiliated hospital, Bandar Abbas, Iran, in the years 2015 - 2016. Patients were divided into two groups based on a random sample table of the lock. Both groups received Magnesium Sulfate through the cardiopulmonary bypass pump. Lidocaine 2% (100 mg) and Amiodarone (300 mg) were injected respectively to group Lidocaine + Magnesium Sulfate (LM) and group Amiodarone + Magnesium Sulfate (AM) patients before aortic cross - clamp release. The incidences of arrhythmias were recorded within 30 minutes after release of the aortic cross - clamp (ACC). Additionally, the defibrillation shocks (frequency and level of Joules delivered), amount of inotrope agent, and the hemodynamic and arterial blood gas parameters were recorded up to 24 hours postoperatively.
Results: There was no significant difference between the two groups in terms of demographic characteristics, ejection fraction, and ASA class. The prevalence of ventricular fibrillation (VF) and atrial fibrillation (Af) 30 minutes after ACC release were 46.7% and 53.3% (P = 0.240) vs. 33.3% and 66.7% (P > 0.999); while, up to 24 hours post - operatively were 60% and 20.0% vs. 0.0% and 0.0% in groups LM and AM respectively. The number of defibrillations in the Lidocaine + Magnesium Sulfate group was significantly higher; 57.9% vs. 25% in groups LM and AM respectively (P = 0.004).
Conclusions: The use of Amiodarone + Magnesium Sulfate reduces the number of defibrillation following the release of the Aortic cross - clamp compared with Lidocaine + Magnesium Sulfate.

Keywords